<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024072</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-19-001</org_study_id>
    <nct_id>NCT04024072</nct_id>
  </id_info>
  <brief_title>To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes</brief_title>
  <official_title>Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Ophthalmic Suspension 1% to Azopt® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of Perrigo's product to an FDA approved product in the
      treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">February 26, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in intra-ocular pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>mean change in intra-ocular pressure of both eyes at four time points : at approximately 8:00 a.m. (hour 0; before the morning drop) and approximately 10:00 a.m. (hour 2) on Day 14 (Week 2) and Day 42 (Week 6) visits.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Perrigo active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Azopt ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 1% ophthalmic suspension</intervention_name>
    <description>Test product</description>
    <arm_group_label>Perrigo active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azopt 1% Ophthalmic Suspension</intervention_name>
    <description>Reference product</description>
    <arm_group_label>Reference active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or
             ocular hypertension in both eyes

          2. Subject requires treatment of both eyes and is able to discontinue use of all ocular
             hypotensive medication(s) or switch ocular hypotensive medications and undergo
             appropriate washout period.

          3. Adequate wash-out period prior to baseline of any ocular hypotensive medication.

          4. Baseline (Day 0/hour 0) pressure ≥ 22 mm Hg and ≤ 34 mm Hg in each eye and any
             asymmetry of pressure between the eyes no greater than 5 mm Hg.

          5. Baseline best corrected visual acuity equivalent to 20/200 or better in each eye

        Exclusion Criteria:

          1. Females who are pregnant, breast feeding, or planning a pregnancy.

          2. Females of childbearing potential who do not agree to utilize an adequate form of
             contraception

          3. Current, or past history of, severe hepatic or renal impairment

          4. Current, or history within two months prior to baseline of, significant ocular
             disease, e.g., corneal edema, uveitis, ocular infection, or ocular trauma in either
             eye

          5. Current corneal abnormalities that would prevent accurate readings with the Goldmann
             applanation tonometer

          6. Functionally significant visual field loss

          7. Contraindication to brinzolamide or sulfonamide therapy or known hypersensitivity to
             any component of brinzolamide or sulfonamide therapy

          8. Use at any time prior to baseline of an intraocular corticosteroid implant

          9. Use within one week prior to baseline of contact lens

         10. Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, or 2)
             topical corticosteroid

         11. Use within one month prior to baseline of: 1) systemic corticosteroid or 2) high-dose
             salicylate therapy

         12. Use within six months prior to baseline of intravitreal or subtenon injection of
             ophthalmic corticosteroid

         13. Having undergone within six months prior to baseline any other intraocular surgery
             (e.g., cataract surgery)

         14. Having undergone within twelve months prior to baseline refractive surgery, filtering
             surgery, or laser surgery for pressure reduction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>James D. Branch Ophthalmology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

